A phase III, randomized, assessor-blinded, active-controlled, multicenter study of the efficacy and safety of APO-EPO as compared to Procrit when given subcutaneously to patients with anemia of chronic kidney disease stage 5D who are currently not on epoetin replacement therapy
Latest Information Update: 13 Apr 2022
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Apotex
- 25 Jan 2018 New trial record